Research programme: anti-messenger RNA vectors - EngevityAlternative Names: Vigilant vector
Latest Information Update: 02 Apr 2007
At a glance
- Originator University of Florida
- Developer Engevity
- Mechanism of Action RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 15 Apr 2003 Preclinical trials in Myocardial infarction in USA (unspecified route)